Curcumin inhibits prostate cancer by upregulating miR‐483‐3p and inhibiting UBE2C

Abstract

Prostate cancer (PCa) is an extremely common genitourinary malignancy among elderly men. Many evidence have shown the efficacy of curcumin (CUR) in inhibiting the progression of PCa. However, the pharmacological function of CUR in PCa is still not quite clear. In this research, CUR was found to suppress the proliferation and enhance the apoptotic rate in in vitro PCa cell models in a dose‐ and time‐dependent manner. In a xenograft animal model, the administration of CUR contributed to a significant decrease in the growth of the xenograft tumor induced by the transplanted PC‐3 cells. Ubiquitin‐conjugating enzyme E2 C is implicated in the modulation of multiple types of cancers. In humans, the expression levels of UBE2C are significantly higher in PCa versus benign prostatic hyperplasia. Treatment with CUR decreased the expression of UBE2C, whereas it increased miR‐483‐3p expression. In contrast with the control mice, the CUR‐treated mice showed a significant reduction in UBE2C and Ki‐67 in PCa cells. The capability of proliferation, migration, and invasion of PCa cells was inhibited by the knockdown of UBE2C mediated by siRNA. Furthermore, dual luciferase reporter gene assay indicated the binding of miR‐483‐3p to UBE2C. In summary, CUR exerts its antitumor effects through regulation of the miR‐483‐3p/UBE2C axis by decreasing UBE2C and increasing miR‐483‐3p. The findings may also provide new molecular markers for PCa diagnosis and treatment.